News summary

Parkinson’s test-and-drug duo wins CPHI award

Source: Longevity Technology • Published: 20 Oct 2026, 16:50

Summarized by Masters of Longevity from Longevity Technology.

A biotech-industry award story about a company pairing a diagnostic test with a matching drug candidate, and what that pairing could mean for future trials and development.

Parkinson’s test-and-drug duo wins CPHI award
Key Takeaways
  • Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.
  • The jury at CPHI Milan had a pattern to break.
  • For three years running, the API Development and Innovation award had gone to manufacturers with new production processes.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.